Pooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients

THLBB206

---

Time: 15:20
Speaker: Calvin Cohen





For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.